Fight AIDS, Tuberculosis and Malaria (GFATM) [3] [4] [5] . Treatment efforts have been accompanied by a national AIDS plan for drug distribution, creation of a more comprehensive health care infrastructure, and establishment of treatment guidelines [6] . Even with these remarkable expansions in capacity, however, the enormity of the epidemic continues to overwhelm the treatment systems; by the end of 2006, ART was reaching fewer than 33% of eligible patients in South Africa [7] .
For development of health policy, it is useful to quantify the potential consequences of disease outcomes under different treatment and practice scenarios [8] . To this end, our objective was to project alternative ART rollout scenarios over the next several years in South Africa. The goals were to forecast the number of lives lost while awaiting needed therapy, to estimate the number of people both in and out of care, and to project when and whether HIV treatment needs would be fully met. These estimates can be used to inform decisions regarding the lifesaving value of alternative treatment expansion scenarios in South Africa, as well as in other developing countries.
METHODS

Analytic Framework
We conduct this analysis in 4 steps. First, we parameterized a detailed computer-based simulation model of HIV disease with data from South Africa. Second, we conducted a series of analyses that assessed the outcomes associated with different ART strategies in selected cohorts of patients. Outcomes included mean CD4 count and HIV RNA levels of the surviving cohort over time, as well as AIDS-related and non-AIDS-related deaths each year. Treatment strategies included no ART and ART that used 2 lines of therapy ("line" here refers to the modeled number of sequential ART regimens available). Each strategy included co-trimoxazole prophylaxis in all scenarios, provided according to WHO guidelines [9] . Cohorts were selected to reflect the fact that in 2007 (the year of the most up-to-date WHO estimates) [2] , patients who met ART eligibility criteria were distributed across HIV disease stages, as well as the fact that in subsequent years, patients who were initially in earlier disease stages progress to meet ART criteria. Third, we used the information generated from the model simulations to assess outcomes associated with different scenarios intended to represent potential populationbased strategies for ART scale-up (table 1) . Outcomes were expressed as number of people alive and on ART, as well as deaths, between 2007-2012. Finally, in sensitivity analyses, we examined the effect of changes in the CD4 count distribution of the cohorts modeled, the number and efficacy of available ART regimens [10, 11] , and the availability of CD4 count monitoring [12] .
CEPAC-International Model and Parameterization
The model. The CEPAC-International Model is a computerbased simulation model of the natural history of HIV infection in different settings; it has been used to estimate the clinical and economic consequences of different strategies for opportunistic infection prophylaxis and ART [13, 14] . We provide a focused description here; further model details have been described elsewhere (see the Appendix, which is available only in the electronic version) [13, 14] . Disease progression was portrayed as a sequence of monthly transitions between health states defined to capture key elements of disease and prognosis. Health states reflected chronic HIV infection, acute illness related to HIV (e.g., opportunistic infection), or death. Health states were stratified by HIV RNA level (Ͼ30,000 copies/mL; 10,001-30,000 copies/ mL; 3,001-10,000 copies/mL; 501-3,000 copies/mL and 500 copies/mL), which informs the monthly rate of decline in CD4 count. In turn, CD4 count (50 cells/L, 51-200 cells/L, 201-350 cells/L, 351-500 cells/L, and Ͼ500 cells/L) informs the monthly risk of opportunistic infection and death (table 2) . Clinical decisions, such as the initiation of ART, were based on clinical findings and, when available, CD4 count and HIV RNA results. Patients on effective ART experience monthly increases in CD4 count, reducing their risk of opportunistic infections and death. After virologic failure, CD4 counts decline, with a concomitant increase in the risk of opportunistic infections. Patients who remain on ART despite virologic failure continue to have some reduction in risk of opportunistic infections and mortality a Risk is stratified by CD4 cell count; in nearly all cases, monthly risk increased with decreasing CD4 count. The following 5 severe opportunistic infections were considered late stage and were used to trigger initiation of antiretroviral therapy: severe fungal infections, isosporiasis, cerebral toxoplasmosis, non-tuberculous mycobacteriosis, and other severe illnesses.
b The percentage monthly risk of mild fungal infections is increased by 46.4% in the presence of co-trimoxazole [14] .
independent of CD4 count [20] , compared with patients who do not continue therapy. The model specified the most prevalent opportunistic infections in South Africa and divided them into 8 severe and 3 mild categories (table 2) .
Model input parameters. Model input data are summarized in table 2 [14 -19, 22] . Model results for both the treated and untreated cohorts were validated with current HIV-related death rates in South Africa [21, 22] . Data on the monthly risk of opportunistic infection were derived from a Cape Town cohort of 2,080 patients followed up longitudinally since 1984 [16, [23] [24] [25] . They were stratified by CD4 count, and the highest risk of opportunistic infection occurred in the lower strata [16, [23] [24] [25] . Co-trimoxazole is effective in preventing several of these opportunistic infections (e.g., Pneumocystis jiroveci pneumonia [formerly Pneumocystis carinii pneumonia], toxoplasmosis, and some bacterial infections), though it may also increase the risk of mild fungal infections [14] .
A first-line, nonnucleoside reverse transcriptase inhibitorbased regimen (in combination with 2 nucleoside reverse transcriptase inhibitors [NRTIs]) had a 48-week HIV RNA suppression rate of 84%, with a mean CD4 count increase of 184 cells/L [17, 18] . Upon observed clinical or immunologic failure of the first-line regimen, the efficacy of a second-line regimen, if available, presumed the addition of a ritonavir-boosted protease inhibitor. This second-line regimen provided a 48-week HIV RNA suppression rate of 71% and a corresponding CD4 count increase of 151 cells/L [19] .
Cohort Descriptions
We distinguished patients who required therapy in 2007 (hereafter, the "prevalent cohort") from those who would need therapy in the period from 2008 -2012 (hereafter, the "incident cohort"). The outcomes of both cohorts were examined for both the ART and "no ART" strategies. We defined patients in need of ART as those who met the current South African criteria that define ART eligibility, regardless of whether the patient had been identified as having HIV infection [26, 27] . These criteria include WHO Stage 4 AIDSdefining illness and/or symptomatic disease with a CD4 count Ͻ200 cells/L [26, 27] . In the base case, there is no prioritization for ART; that is, among those eligible, patients are randomly chosen for ART and are not given preference based on CD4 count, degree of "AIDS sickness," or time waiting for ART.
Patients in need of therapy in 2007. We began the time horizon with the most recent WHO estimates (2007), when there were an estimated 1,000,000 patients in South Africa in need of therapy [2] . To approximate the distribution of stage of illness for these patients, we assumed that the South Africa epidemic was in a steady state and that the number of incident cases each year remained the same over the 10-year period prior to ART rollout (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) . As noted above, we refer to this cohort as the prevalent cohort.
Patients who require therapy in the future (2008 -2012). Patients become newly eligible for therapy each year from 2008 -2012. This reflects the fact that incident cases of HIV will occur, and that existing patients with early infection will progress to a point at which they are eligible for ART. Approximately 5.51 million people are estimated to be living with HIV/ AIDS in South Africa [2, 28] . With a mean 10-year progression from HIV infection to AIDS [29] , we estimated that 10% of those 5.51 million infected people (or 551,000 people) would be newly in need of therapy in each year. As noted above, we refer to this group as the incident cohort.
Derivation of initial mean CD4 counts of the cohorts. The mean CD4 count of the prevalent and incident cohorts were obtained from the CEPAC-International Model. The incident cohort was derived first. The characteristics of the incident cohort, which becomes eligible for ART in yearly cycles, are obtained by tracking the course of HIV disease for a relatively healthy starting cohort (CD4 count, mean Ϯ SD, 534 Ϯ 100 cells/L) that received only co-trimoxazole prophylaxis [30] . The model records and averages the clinical characteristics of patients (e.g., CD4 count, HIV RNA levels, and opportunistic infection history) as they reach the criteria for ART eligibility (CD4 Ͻ 200 cells/L or severe opportunistic infection). The resulting incident cohort had a mean (ϮSD) CD4 count of 210 (Ϯ 50) cells/L.
The prevalent cohort was a heterogeneous distribution of patients who had been in need of ART for varying amounts of time. The characteristics of the prevalent cohort were obtained by simulating and tracking the course of HIV disease for an incident cohort as described above (CD4 count, mean Ϯ SD, 210 Ϯ 50 cells/L) that receives co-trimoxazole prophylaxis only [14] . Thus, the 1997 cohort was followed for 10 years, whereas the 2006 cohort was followed for 1 year. We then calculated a weighted average of CD4 count and HIV RNA distribution on the basis of the population distribution of all patients who were alive at the end of the 10-year period. The patients alive at the beginning of the ART rollout period consisted mostly of the cohort that had become eligible in 2006 (44% of the patients alive at beginning of the rollout period), whereas patients who had reached the eligibility criteria in 1997 but were not treated constituted less than 0.01% of those still alive in 2007. The resulting cohort (i.e., the prevalent cohort) had a mean (ϮSD) CD4 count of 92 (Ϯ 49) cells/L.
Scenarios Examined
We examined 5 population-based strategies of ART scale-up based, in part, on projections made by the Actuarial Society of South Africa, the South African Joint Task Force, and the WHO [6, 28, 31] . These scenarios (table 1) range from a situation in which no new treatment funds are allocated (zero growth) to a situation in which a rapid and aggressive scale-up program is initiated (rapid growth) [32, 33] . We consider the full capacity scale-up program only for purposes of comparison.
Using WHO surveillance data and model-generated mortality rates, we projected the number of deaths under each scenario. Each year, mortality was calculated to include deaths that occurred among patients who needed, but had not yet received, ART, in addition to deaths that occurred-albeit later and at a slower rate-among patients who received ART. For patients who died while receiving ART, we assumed that their treatment slots (which reflected unused medications and human resources) would be available for other patients in the following year. In each scenario, the total deaths and total life years of survival were tallied and reported from 2007-2012.
RESULTS
Survival Rates
Assessment of model performance. To ensure that modelbased death rates were appropriate for long-term projections, we compared them to reported survival trends in South Africa, both for patients who received ART and those who did not. At each yearly time point, model-based estimates were within 10% of reported survival (see the Appendix, which is available only in the electronic version) [21] .
Projected survival with and without ART for both cohorts. Patients who entered the model in the prevalent cohort (2007; mean CD4 count, 92 cells/L) and received ART in that year had 1-and 5-year projected survival rates of 94% and 70%, respectively. If they did not receive ART, these patients had markedly reduced survival rates of 55% at 1 year and 1% at 5 years. For patients in the comparatively healthier incident cohort (2008 -2012, mean CD4 count, 210 cells/L) who received ART as recommended without delay, 1-and 5-year survival rates were 94% and 72%, respectively. If the patients did not receive ART, the corresponding 1-and 5-year survival rates for the incident cohort were 79% and 4%.
Number of Patients Who Received ART for Each Scenario
For each scale-up scenario, we examined the number of people alive and on ART at the end of each year, comparing the current study to published South African projections (figure 1). By 2012, if all patients received ART in the year that they first met eligibility criteria (full capacity), 2.9 million people would be alive and receiving treatment in 2012. The rapid-growth scenario results in 2.5 million people receiving treatment, compared to 2.2 million in the moderategrowth scenario, 831,000 in the constant-growth scenario, and 364,000 in the zero-growth scenario. Figure 2 illustrates the percentage of patients alive and eligible each year who received ART. All of the patients who needed ART had access by 2011 in the rapid-growth scenario; the moderategrowth scenario met 97% of treatment need by 2012. In 2012, the constant-growth scenario met only 52% of the treatment need; the zero-growth scenario-with no new treatment slots available after 2007-met just 28% of the treatment need by 2012 (figure 2).
Mortality Projections for Each Scenario
The number of deaths projected to occur before patients started ART and while patients were receiving ART were also calculated for each of the scenarios ( figure 3 ). The total number of deaths increases over time in the zero-growth scenario due to a yearly influx of patients who require treatment (the incident cohort) without the provision of any new treatment resources. The rapid-growth scenario results in notably fewer deaths than all the other scenarios (except full capacity, which is provided for purposes of comparison). The increase in deaths under the rapidgrowth scenario in 2010 -2012 reflects patients who received ART during earlier years of their illness but who subsequently failed ART, and who die several years after treatment initiation. Table 3 summarizes outcomes associated with the nearly 3.8 million patients eligible for therapy in the time horizon considered. The total number of deaths over 6 years ranged from 2.5 million under the zero-growth scenario to 1.2 million under the rapid-growth scenario. Compared with the zero-growth scenario, the constantgrowth and moderate-growth scenarios averted 305,000 and 1,000,000 more deaths through 2012, respectively.
In a sensitivity analysis, we examined the assumption that patients in need of ART are prioritized on the basis of the length of time they have been eligible for therapy (table 3) . For example, in this prioritized scenario, the whole 2007 prevalent cohort would be treated before anyone in the 2008 incident cohort received therapy. This sort of prioritization, on average, treats the sickest patients (i.e., those with the lowest CD4 counts) first. For each scenario, prioritization led to fewer deaths over the 6-year time horizon, compared with the base case analysis. Comparison of each scenario with its nonprioritized counterpart showed between 17,000 (zero-growth scenario) and 87,000 (moderategrowth scenario) fewer deaths over 6 years.
We also examined the availability of only 1 line of ART (rather than 2 successive lines), changes in the efficacy of second-line therapy, the availability of 3 successive lines of ART, and a sce- , and all scenarios included the availability of 2 successive lines of therapy. The estimated number of deaths each year for those awaiting antiretroviral therapy (ART) and those receiving ART were calculated for each scale-up scenario by use of mortality rates generated from model output. Annual mortality rates for both the prevalent and incident cohorts were stratified by treatment status (awaiting ART or receiving ART) and length of time awaiting therapy. nario in which no CD4 count monitoring was available. Compared with scenarios in which there were no CD4 tests available, the availability of CD4 testing resulted in 102,000 -986,000 fewer deaths over 6 years. For each scenario, more deaths occurred when there were 2 lines of therapy and no CD4 monitoring available, compared with only 1 line of therapy and CD4 monitoring. Finally, varying the assumption regarding the efficacy of ART in preventing severe opportunistic infections, independent of CD4 count, produced quantitative changes in the survival rate but had no material impact on the qualitative findings.
DISCUSSION
We used a model-based analysis and South African data to project the average impact of alternative ART strategies over the next 5 years. We applied these strategies to different cohorts, which were intended to be representative of patients who were eligible for ART in 2007, patients who will be eligible for ART from 2008 -2012, and patients who have been waiting for ART for varying periods of time. We aggregated the results of these cohorts to create a comparative analysis of population-based scenarios for ART scale-up.
The findings suggest that the potential loss of life associated with the failure to provide ART to all who need it, in South Africa alone, is enormous. A scenario that maintains current treatment capacity with no addition of treatment resources over the long term (zero growth) will result in over 1.2 million more deaths in South Africa-a country with a population of 48 million people [34] -by 2012, compared with a scenario that provides the resources to ensure universal access to ART by 2011 (rapid growth). The current projected time line for ART scale-up in South Africa (2.1 million receiving treatment by 2012, or a moderate-growth scenario) will likely result in nearly 1.5 million deaths through 2012, over 200,000 more than would be seen with rapid growth [35] . ART guidelines are generally country-specific and vary widely [36] . Some countries, for example, Malawi, do not recommend CD4 count monitoring, and ART initiation is based on WHO stage-3 or stage-4 disease, or CD4 count, if available [37] . Patients are now being enrolled in trials to examine the long-term impact of clinical monitoring versus laboratory monitoring while on ART, because earlier reports from programs that used clinical guidelines alone suggest substantial survival benefits, even without CD4 count monitoring [12] . These reports are consistent with the results reported here, however, without access to CD4 monitoring, the number of deaths through 2012 may increase by as many as 986,000, compared with similar scale-up scenarios in which CD4 monitoring is available. Indeed, these results emphasize that the addition of any ART regimen will greatly improve survival; however, they also highlight that the benefits of ART will be maximized with the addition of CD4 counts, as is current South Africa policy.
This analysis has several limitations. It does not compare different strategies for the operational delivery of ART (an essential component to effective scale-up), nor does it include unintended negative consequences of ART. Importantly, we also do not discuss the opportunity costs of investment in expanded ART. One South African projection estimates that full HIV treatment coverage by 2010 -including the costs of antiretroviral drugs, nutritional support, and non-antiretroviral drugs-will cost 16.9 -21.4 billion Rand in South Africa (US$2.54 -3.22 billion) [38] . Although we have not addressed societal trade-offs in this paper, this analysis offers a quantitative assessment of the opportunity cost-in lives lost-of failing to make these investments in HIV care.
Beyond economic requirements, other complicated infrastructure issues cannot be overlooked and must play a role in any ART implementation. These include facilities, personnel, equipment, and political will. A goal of rapid scale-up must also be accompanied by a commitment to adequate monitoring of therapy, to avoid depletions of stock and interruptions in drug delivery, and to ensure patient adherence so that drug resistance does not occur. Recent findings on the role of extensively drugresistant tuberculosis (XDR-TB) suggest that the implementation of a large-scale ART program in South Africa will require improvements in tuberculosis control programs as well, to maximize the survival benefits conferred by ART [39] . The rising prevalence of drug-resistant strains of tuberculosis, coupled with the high mortality rate among HIV-infected patients with XDR-TB, risks considerably undermining the benefits of ART in South Africa [39] . Infrastructure improvements for the care of individuals with HIV infection and tuberculosis are particularly important, given the possibility that XDR-TB may be transmitted in healthcare settings, thus putting HIV patients who seek medical care at greater risk of infection with this virulent tuberculosis strain [39] .
As with all model-based analyses, data were derived from multiple sources, which contributes to some uncertainty in the model projections. In most cases, data are specifically from South Africa. However, when South African data were unavailable, we used the closest appropriate surrogate data. To ensure that the model outcomes adequately reflect the South African context, we provided validation from the South African natural history and treatment literature. The estimates of mean CD4 count in the population were made under the assumption of an HIV epidemic in steady state. We have addressed this assumption via sensitivity analyses, examining the parameters that might be most influential in the overall results. The analysis of prioritization made ART available first to those who had been waiting longest. On average, this meant prioritizing those with the lowest CD4 count (mean CD4 count when receiving ART after a wait of 1 year was 139 cells/L, compared with a CD4 count of 210 cells/L for those who received ART immediately), though this might not be true in every case.
Though the goal is ambitious, ART scale-up efforts to date have been impressive. The number of people receiving ART in lowincome and middle-income countries worldwide increased more than five fold between 2001 and 2005, from 240,000 to 1.3 million [1] . This level of achievement was previously thought to be impossible. Deliberate, purposeful, and expedient scale-up-together with careful analysis of the outcomes associated with different programmatic approaches-will make the difference in saving hundreds of thousands, or millions, of lives.
